1995S-0316
RPT 263
Volume 192

Cover Page

Letter from CFSAN to Nutrition 21

New Dietary Ingredient Notification for Arginine Silicate Inositol (ASI) Complex

Appendix 1 - Product Specifications and Certificates of Analysis

Appendix 2 - References

Adams, M.R.; Forsyth, C.J.; Jessup, W.; Robinson, J.; Celermajer, D.S. 1995. Oral L-arginine inhibits platelet aggregation but does not enhance endothelium-dependent dilation in healthy young men. J Am Coll Cardiol 26(4):1054-1061.

Adams, M.R.; McCredie, R.; Jessup, W.; Robinson, J.; Sullivan, D.; Celermajer, D.S. 1997. Oral L-arginine improves endothelium-dependent dilatation and reduces monocyte adhesion to endothelial cells in young men with coronary artery disease. Atherosclerosis 129(2):261-269.

Aeschbacher, H.U.; Chapple, C.; Manganal, M.; Aeschbacher, R. 1981. Investigation of Maillard products in bacterial mutagenicity test systems. Prog Food Nutr Sci 5279-294.

Aji, W.; Ravalli, S.; Szabolcs, M.; Jiang, X.C.; Sciacca, R.R.; Michler, R.E.; Cannon, P.J. 1997. L-arginine prevents xanthoma development and inhibits atherosclerosis in LDL receptor knockout mice. Circulation 95(2):430-437.

Barak, Y.; Levine, J.; Glasman, A.; Elizur, A.; Belmaker, R.H. 1996. lnositol treatment of Alzheimer’s disease: A double blind, cross-over placebo controlled trial. Prog Neuropsychopharmacol Biol Psychiatry 20(4):729-735.

Barbul, A. 1986. Arginine: biochemistry, physiology, and therapeutic implications. JPEN J Parenter Enteral Nutr 10(2):227-238. Cited In: FASEB, 1992.

Barbul, A.; Lazarou, S.A.; Efron, D.T.; Wasserkrug, H.L.; Efron, G. 1990. Arginine enhances wound healing and lymphocyte immune responses in humans. Surgery 108(2):331-336 & Discussion, pp. 336-337. Cited In: FASEB, 1992.

Benjamin, J.; Levine, J.; Fux, M.; Aviv, A.; Levy, D.; Belmaker, R.H. 1995. Double-blind, placebo-controlled, crossover trial of inositol treatment for panic disorder. Am J Psychiatry 152(7):1084-1086.

Brusilow, S.W.; Horwich, A.L. 1989. Urea cycle enzymes. b: Striver CR.; Beaudet, A.L.; Sly, W.S.; Valle, D. (Eds.). The Metabolic Basis of Inherited Disease (6th Ed.). McGraw Hill, Inc.; New York, pp. 629-663. Cited In: FASEB, 1992.

Chan, J.R.; Boger, R.H.; Bode-Bbger, S.M.; Tangphao, 0.; Tsao, P.S.; Blaschke, T.F.; Cooke, J.P. 2000. Asymmetric dimethylarginine increases mononuclear cell adhesiveness in hypercholesterolemic humans. Arterioscler Thromb Vast Biol 20(4):1040-1046.

Cheng, J.W.M.; Baldwin, S.N. 2001. L-arginine in the management of cardiovascular diseases. Ann Pharmacother 35(6):755-764 [Erratum, 35(7&8):965].

Colodny, L.; Hoffman, R.L. 1998. Inositol--clinical applications for exogenous use. Altern Med Rev 3(6):432-447.

Devine, J. (Jr.). 2003. An Acute Oral Limit Test of Arginine Silicate lnositol Complex in the Rat: Final Report of the Study [Confidential]. BAS; Evansville. [Study No. 743A-101-010-03].

Drago, F.; Continella, G.; Alloro, M.C.; Auditore, S.; Pennisi, G. 1984. Behavioral effects of arginine in male rats. Pharmacol Res Commun 16(9):899-907.

Edmonds, M.S.; Gonyou, H.W.; Baker, D.H. 1987. Effect of excess levels of methionine, tryptophan, arginine, lysine or threonine on growth and dietary choice in the pig. J Anim Sci 65: 179-185.

Einat, H.; Belmaker, R.H.; Kopilov, M.; Klein, E.; Gazawi, H.; Ben-Shachar, D. 1999a. Rat brain monoamines after acute and chronic myo-inositol treatment. Eur Neuropsychopharmacol 10(1):27-30.

Einat, H.; Karbovski, H.; Korik, J.; Tsalah, D.; Belmaker, R.H. 1999b. Inositol reduces depressive-like behaviors in two different animal models of depression. Psychopharmacology 144(2):158-162.

FASEB. 1992. Safety of Amino Acids Used in Dietary Supplements. Prepared by: U.S. Food and Drug Administration (U.S. FDA), Center for Food Safety and Applied Nutrition (CFSAN); Washington, DC for Life Sciences Research Office (LSRO), Federation of American Societies for Experimental Biology (FASEB); Bethesda, Maryland.

FDA. 1993. Priority Based Assessment of Food Additives (PAFA) Database. Food and Drug Administration (FDA), Center for Food Safety and Applied Nutrition (CFSAN); Washington, DC.

FDA. 2004. Code of Federal Regulations. Title 21 - Food and Drugs. [Parts §160.105; §169.179; §172.320; §173.310; §182.1045; §182.1711; §182.2729; §184.1370; §184.1 (b)(1); §184.1069]. Food and Drug Administration, U.S. (FDA); Washington (DC).

Gudi, R.; Krsmanovic, L. 2004. Mammalian Erythrocyte Micronucleus Test: Arginine Silicate Inositol Complex: Final Report [Confidential]. Tested by BioReliance; Rockville, Maryland, Sponsored by Nutrition 21, Inc.; Purchase, New York. [Bioreliance Study Number: AA75TT.123.BTL].

Gudi, R.; Rao, M. 2004. In Vitro Mammalian Chromosome Aberration Test: Arginine Silicate Inositol Complex: Final Report [Confidential]. Tested by BioReliance; Rockville, Maryland, Sponsored by Nutrition 21, Inc.; Purchase, New York. [Bioreliance Study Number: AA75TT.331.BTL].

Hecht, S.S.; Kenney, P.M.; Wang, M.; Upadhyaya, P. 2001. Dose-response study of myoinositol as an inhibitor of lung tumorigenesis induced in A/J mice by benzy[a]pyrene and 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone. Cancer Lett 167(1):1-6.

ICH. 1996. Guidance on Specific Aspects of Regulatory Genotoxicity Tests for Pharmaceuticals: Recommended for Adoption at Step 4 of the ICH Process on 16 July 1995 by the ICH Steering Committee [S2A]. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH). ICH Harmonised Tripartite Guideline.

ICH. 1997. Genotoxicity: A Standard Battery for Genotoxicity Testing of Pharmaceuticals: Recommended for Adoption at Step 4 of the ICH Process on 16 July 1997 by the ICH Steering Committee [S2B]. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH). ICH Harmonised Tripartite Guideline.

IOM. 2001. Arsenic, boron, nickel, silicon, and vanadium. In: Dietary Reference Intakes for Vitamin A, Vitamin K, Arsenic, Boron, Chromium, Copper, Iodine, Iron, Manganese, Molybdenum, Nickel, Silicon, Vanadium and Zinc. Panel on Micronutrients, Subcommittees on Upper Reference Levels of Nutrients and of Interpretation and Use of Dietary Reference Intakes, and the Standing Committee on the Scientific Evaluation of Dietary Reference Intakes, Food and Nutrition Board, Institute of Medicine (IOM). National Academy Press (NAP); Washington, DC, pp. 502-553.

IOM. 2002. Dietary carbohydrates: Sugars and starches. In: Dietary Reference Intakes for Energy, Carbohydrate, Fiber, Fat, Fatty Acids, Cholesterol, Protein, and Amino Acids (Macronutrients). Institute of Medicine (IOM) of the National Academies /The National Academy Press (NAP); Washington, DC, pp. 207-264.

Jeremy, R.W.; McCarron, H.; Sullivan, D. 1996. Effects of dietary L-arginine on atherosclerosis and endothelium-dependent vasodilatation in the hypercholesterolemic rabbit. Response according to treatment duration, anatomic site, and sex. Circulation 94(3):498-506.

Jugdaohsingh, R.; Reffitt, D.M.; Oldham, C.; Day, J.P.; Fifield, L.K.; Thompson, R.P.; Powell, J.J. 2000. Oligomeric but not monomeric silica prevents aluminum absorption in humans. Am J Clin Nutr 71(4):944-449.

Jugdaohsingh, R.; Anderson, S.H.; Tucker, K.L.; Elliott, H.; Kiel, D.P.; Thompson, R.P.; Powell, J.J. 2002. Dietary silicon intake and absorption. Am J Clin Nutr 75(5):887-893.

Kada, T.; Hirano, K.; Shirasu, Y. 1980. Screening of environmental chemical mutagens by the Rec-assay system with Bacillus subtilis. In: de Serres, F.J.; Hollaender, A. (Eds.). Chemical Mutagens: Principles and Methods for Their Detection: Vol. 6. Environmental Mutagenesis Society. Plenum Press; New York, pp. 149-173.

Kanematsu, N.; Hara, M.; Kada, T. 1980. Rec assay and mutagenicity studies on metal compounds. Mutat Res 77(2):109-116.

Kang, S.S.; Wong, P.W.K.; Melyn, M.A. 1983. Hyperarginemia: Effect of ornithine and lysine supplementation. J Pediatr 103:763-765. Cited In: FASEB, 1992.

Kettner, A.; Silbernagl, S. 1984. Citrulline transport and metabolism in the kidney. Eur J Clin Invest 14(2, Part 2):52 [Abstract No. 310].

Kilberg, M.S. 1982. Amino acid transport in isolated rat hepatocytes. J Membr Biol 69:1-12.

Kofman, O.; Agam, G.; Shapiro, J.; Spencer, A. 1998. Chronic dietary inositol enhances locomotor activity and brain inositol levels in rats. Psychopharmacology 139(3):239-242. Cited In: Einat et al., 1999a.

Lang, K.J.; Nielsen, B.D, Waite, K.L.; Hill, G.M.; Orth, M.W. 2001. Supplemental silicon increases plasma and milk silicon concentrations in horses. J Anim Sci 79(10):2627-2633.

Lerman, A.; Burnett, J.C. (Jr.); Higano, S.T.; McKinley, L.J.; Holmes, D.R. (Jr.). 1998. Longterm L-arginine supplementation improves small-vessel coronary endothelial function in humans. Circulation 97(21):2123-2128.

Levine, J. 1997. Controlled trials of inositol in psychiatry. Eur Neuropsychopharmacol 7(2):147-155.

Levine, J.; Barak, Y.; Gonzalves, M.; Szor, H.; Elizur, A.; Kofman, O.; Belmaker, R.H. 1995. Double-blind, controlled trial of inositol treatment of depression. Am J Psychiatry 152(5):792-794.

Loomis, T.A. 1978. Numbers in toxicology. In: Essentials of toxicology (3rd Ed.). Lea & Febbiger; Philadelphia, pp. 13-28. Cited In: Devine, 2003.

Luiking, Y.C.; Weusten, B.L.; Portincasa, P.; Van Der Meer, R.; Smout, A.J.; Akkermans, L.M. 1998. Effects of long-term oral L-arginine on esophageal motility and gallbladder dynamics in healthy humans. Am J Physiol 274(6, Part l):G984-G991.

Maxwell, A.J.; Ho, H.-K.V.; Le, C.Q.; Lin, P.S.; Bernstein, D.; Cooke, J.P. 2001. L-arginine enhances aerobic exercise capacity in association with augmented nitric oxide production. J Appl Physiol 90(3):933-938.

McClendon, J.F.; Gershon-Cohen, J.; Brody, H. 1958. Absence of gastrointestinal lesions in rats following ingestion of silica. Proc Soc Exp Biol Med 97:330-331.

Merck. 2001. The Merck Index, Thirteenth Edition. An Encyclopedia of Chemicals, Drugs and Biologicals. Whitehouse Station, NJ: Merck & Co., Inc.

Milner, J.A.; Stepanovich, L.V. 1979. Inhibitory effect of dietary arginine on growth of Ehrlich ascites tumor cells in mice. J Nutr 109(3):489-494. Cited In: FASEB, 1992.

Naidu, R.C. 1973. The effect of L. arginine hydrochloride on the development of rat embryos. Aust J Exp Biol Med Sci 51(4):553-555.

Nelson, D.L.; Cox, M.M. 2000. Lipid biosynthesis. In: Lehninger Principles of Biochemistry. Worth Publishers, Inc.; New York, pp. 92-93.

Newberne, P.; Smith, R.L.; Doull, J.; Goodman, J.I.; Munro, l.c.; Portoghese, P.S.; Wagner, B.M.; Weil, C.S.; Woods, L.A.; Adams, T.B.; Hallagan, J.B.; Ford, R.A. 1998. GRAS flavoring substances 18. Food Technol 52(9):65-92.

OECD. 1992. Acute oral toxicity [Guideline No. 401]. 7: OECD Guidelines for the Testing of Chemicals. Organization for Economic Co-operation and Development (OECD); Paris.

OECD. 1997. Genetic toxicology: Bacterial reverse mutation test [Guideline No. 471]. In: OECD Guidelines for the Testing of Chemicals. Organization for Economic Cooperation and Development (OECD); Paris.

OECD. 1998a. In vitro mammalian chromosome aberration test [Guideline No. 473]. In: OECD Guidelines for the Testing of Chemicals. Organization for Economic Co-operation and Development (OECD); Paris.

OECD. 1998b. Genetic toxicology: Mammalian erythrocyte micronucleus test [Guideline No. 474]. In: OECD Guidelines for the Testing of Chemicals. Organization for Economic Co-operation and Development (OECD); Paris.

Park, K.G.; Heys, S.D.; Blessing, K.; Kelly, P.; McNurlan, M.A.; Eremin, O.; Garlick, P.J. 1992. Stimulation of human breast cancers by dietary L-arginine. Clin Sci (Lond) 82(4):413- 417. Cited In: FASEB, 1992.

PDR. 2003. Physicians’ Desk Reference For Nonprescription Drugs and Dietary Supplements (24th Ed.). Physicians’ Desk Reference (PDR)/Medical Economics Data Production Company; Demoines, IAIMontvale, NJ.

PDRNS. 2001. PDR For Nutritional Supplements (1st Ed.). Physicians’ Desk Reference (PDR); Demoines, Iowa/Medical Economics Data Production Company; Montvale, New Jersey, pp. 248-254, 315-318 & 424-425.

Pennington, J.A. 1991. Silicon in foods and diets. Food Addit Contam 8(1):97-118.

Preli, R.B.; Klein, K.P.; Herrington, D.M. 2002. Vascular effects of dietary L-arginine supplementation. Atherosclerosis 162(1):1-15.

Rabier, D.; Kamoun, P. 1995. Metabolism of citrulline in man. Amino Acids 9(4):299-316.

Ronnenberg, A.G.; Gross, K.L.; Hartman, W.J.; Meydani, S.N.; Prior, R.L. 1991. Dietary arginine supplementation does not enhance lymphocyte proliferation or interleukin-2 production in young and aged rats. J Nutr 121(8):1270-1278. Cited In: FASEB, 1992.

RTECS. 2000. L-Arginine, Monohydrochloride. Registry of Toxic Effects of Chemical Substances (RTECS); Bethesda, Maryland. [RTECS No. CF1995500]. [http://www.cdc.gov/niosh/rtecs/cf1e72ec.html].

Russell, J.C. 2003. Effects of Dietary Supplementation With Arginine on Metabolism and Vascular Function in the Insulin-Resistant JCR:LA-cp Rat: Nutrition 21 Inc. Final Report [Confidential]. University of Alberta, Department of Surgery for Nutrition 21, Inc.; Purchase, New York.

Seaborn, C.D.; Nielsen, F.H. 1993. Silicon: A nutritional beneficence for bones, brains and blood vessels? Nutr Today 28(July/Aug.):13-18.

T.J. Clark & Co. 2004. Silicon. T.J. Clark & Company. [http://www.ticlarkinc.com/minerals/silicon.htm].

Tachibana K.; Mukai K.; Hiraoka I.; Moriguchi S.; Takama S.; Kishino Y. 1985. Evaluation of the effect of arginine-enriched amino acid solution on tumor growth. JPEN J Parenter Enteral Nutr 9(4):428-434. Cited In: FASEB, 1992.

Takizawa, Y.; Hirasawa, F.; Noritomi, E.; Aida, M.; Tsunoda, H.; Uesugi, S. 1988. Oral ingestion of syloid to mice and rats and its chronic toxicity and carcinogenicity. Acta Med Biol 36(1):27-56.

Tietz, N. 1996. Fundamentals of Clinical Chemistry. W.B. Saunders Company; Philadelphia.

Tsubuku, S.; Hatayama, K.; Mawatari, K.; Smriga, M.; Kimura, T. 2004. Thirteen-week oral toxicity study of L-Arginine in rats. Int J Toxicol 23(2):101-105.

U.S. EPA. 1998. Health Effects Test Guidelines: OPPTS 870.5100: Bacterial Reverse Mutation Test. U.S. Environmental Protection Agency (U.S. EPA); Washington, DC. [http://www.epa.gov/opptsfrs/OPPTS_Harmonized/870_Health_Effects_Test_Guidelines/Series/870-5100.pdf].

Van Dyck, K.; Van Cauwenbergh, R.; Robberecht, H.; Deelstra, H. 1999. Bioavailability of silicon from food and food supplements. Fresenius J Anal Chem 363:541-544.

Xu, Y. 2003. Ames Bacterial Reverse Mutation Test of Arginine lnositol Potassium Silicate Complex: Report [Confidential]. Performed by MicaGenix, Inc., Department of Toxicology; Greenfield, Ind., Sponsored by Nutrition 21, Inc.; Purchase, New York. [Study Number: 042AMSAA04].